Extended high cut-off haemodialysis for myeloma cast nephropathy in Auckland, 2008-2012.
Nephrology (Carlton)
; 19(7): 432-5, 2014 Jul.
Article
en En
| MEDLINE
| ID: mdl-24931113
ABSTRACT
Myeloma cast nephropathy contributes to high morbidity and early mortality associated with the development of end-stage renal disease. Treatment with extended high cut-off haemodialysis coupled with novel anti-myeloma therapies enables significant reduction of serum-free light chains and has been shown to improve renal outcomes. In this case series, medical records of 6 patients who received high cut-off haemodialysis for biopsy-proven cast nephropathy were retrospectively reviewed. Patients received a total of 344 hours of high cut-off haemodialysis and concurrent chemotherapy. Only 50% became dialysis independent following treatment. One patient who achieved sustained remission remained dialysis dependent. The added benefit of high cut-off haemodialysis in the light of novel anti-myeloma therapies requires further evaluation.
Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Pirazinas
/
Talidomida
/
Ácidos Borónicos
/
Dexametasona
/
Leucemia de Células Plasmáticas
/
Diálisis Renal
/
Fallo Renal Crónico
/
Mieloma Múltiple
Tipo de estudio:
Diagnostic_studies
/
Etiology_studies
Límite:
Aged
/
Female
/
Humans
/
Male
/
Middle aged
País como asunto:
Oceania
Idioma:
En
Año:
2014
Tipo del documento:
Article